Syncytial virus: Protection reaches 72.11% in Antofagasta Province

The marketing campaign in opposition to Respiratory Syncytial Virus (RSV) reaches a 72.11% in comparison with yesterday within the Division of Antofagasta, in accordance with data from the Seremi de Salud, so excess of 2,300 youngsters have been vaccinated.

Chile is the primary nation in Latin America to obtain the Monoclonal antibody in Nersevimab to stop RSV, as a part of the Winter 2024 Marketing campaign.

The vaccination course of began on April 1 and can final till the top of September. “These shall be vaccinated newborns between April and September, in addition to the group that’s as much as six months outdated on the time the marketing campaign begins. That’s, these born between October 2023 and March 2024,” defined the Minister of Well being Jessica Bravo.

Inside the goal group in addition they take into account infants who meet the factors set out by the Legislation Ricarte Soto: low beginning weight (lower than 1,500 grams), 32-week untimely infants and people with congenital coronary heart illness.

Figures by group

In line with knowledge printed by the Division of Well being Info Statistics (DEIS) of the Ministry of Well being, to this point 2,371 youngsters have been vaccinated within the Division of Antofagasta, which represents a protection of 72.11%.

The communities that current a higher protection These are Tocopilla (106.19%), Mejillones (86.59%), María Elena (84.62%) and Calama (77.56%).

Alternatively, the communities with much less protection These are Antofagasta (68.04%), San Pedro de Atacama (59.04%), Taltal (58.62%) and Sierra Gorda (50%). Ollagüe doesn’t register a inhabitants within the goal group.

Lastly, keep in mind that the medication is free. Due to this fact, it’s accessible in all group clinics and hospitals within the area, in addition to in non-public vaccination facilities.